A phase 1/2 trial of Herpes Virus C5252 Injection in glioma & glioblastoma, run by ImmVira Pharma Co. Ltd, now recruiting.
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor is a phase 1/2 interventional study registered as NCT07243340 by ImmVira Pharma Co. Ltd, with 36 participants planned, started 2026-04-03 and due to reach its primary completion in 2027-12-15. Interventions recorded: Herpes Virus C5252 Injection.
Shares ImmVira Pharma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares ImmVira Pharma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.